fda shortage list tirzepatide reviews decision to put Lilly's on FDA says that the GLP-1

The outcome data in T1DM is very limited and more data is needed #SGLT2inhibitors #GLP1receptoragonist #SGLT2i #GLP1 #nsMRA #nonsteroidalmineralocorticoidreceptorantagonists #CVcomplications #DKD #cardioprotection #nephroprotection #combinationtherapy Martin Haluzks Post 2, 1- : Very interesting paper recently published in Diabetes Therapy by Elisabeth Buur Stougaard and colleagues

In fact, its the added acetyl group that allows it to cross the blood-brain barrier, which standard L-carnitine doesnt do as easily

Metabolites of omega-3 PUFAs are vital for the synthesis of several inflammatory mediators including prostaglandins (PG), leukotrienes (LT), thromboxanes (TX), protectins , and resolvins 709

Eli Lilly funded both studies

[Abstract] Cell Mol Life Sci

This dual approval marked a turning point in the treatment of obesity and has since generated significant interest among healthcare providers and individuals seeking effective weight loss solutions